ARQT

Arcutis Biotherapeutics, Inc.

Contracts

Total Value

Stock Metrics

13.7%

Short % Float

10.7d to cover · Moderate squeeze

1.1%

Inst % Float

10 holders · 2026-06-30

Suvretta Capital M

Top Holder

9.8% of float

92.6M sh

Public Float

50/100

Dilution Score

Medium

3 mo

Cash Runway

Verified regulatory filings & proprietary analysis.

Dilution Risk

50/100

MEDIUM

Inst: 1.09% · Top: Suvretta Capital Management, LLC

Biotech Analytics

Immuno-Oncology

60.19

Squeeze risk: MODERATE

Insider Buying0

Publications100

Dilution Risk50

Clinical Trials100

Short Interest50